Skip to main content

Hindson Benjamin J.'s Form 4 filing

10x Genomics, Inc. (TXG) · filed Jul 6, 2021

Accession no.
0001209191-21-045469
Filed
Jul 6, 2021
Trade date
Jul 1, 2021
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.98M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hindson Benjamin J.CIK 0001786391Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 1, 2021Class A Common StockMOption exerciseAcquired+41,666$1.20+$49,999.289,120Direct
Jul 1, 2021Class A Common StockSSaleDisposed−9,058$189.80F2−$1,719,208.480,062Direct
Jul 1, 2021Class A Common StockSSaleDisposed−12,845$190.51F3−$2,447,100.9567,217Direct
Jul 1, 2021Class A Common StockSSaleDisposed−7,202$191.58F4−$1,379,759.1660,015Direct
Jul 1, 2021Class A Common StockSSaleDisposed−2,872$192.69F5−$553,405.6857,143Direct
Jul 1, 2021Class A Common StockSSaleDisposed−5,989$193.63F6−$1,159,650.0751,154Direct
Jul 1, 2021Class A Common StockSSaleDisposed−2,500$194.58F7−$486,45048,654Direct
Jul 1, 2021Class A Common StockSSaleDisposed−1,200$195.60F8−$234,72047,454Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 1, 2021Class A Common StockMOption exerciseDisposed−41,666$0.00$071,082Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $189.14 to $190.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $190.14 to $191.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $191.14 to $192.105. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $192.14 to $193.085. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F6

This transaction was executed in multiple trades at prices ranging from $193.15 to $194.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F7

This transaction was executed in multiple trades at prices ranging from $194.17 to $195.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F8

This transaction was executed in multiple trades at prices ranging from $195.23 to $196.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Remarks

Chief Scientific Officer and President

Read the full filing on SEC EDGAR (opens in a new tab)